Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19 | Zendy

Wang-Da Liu | Zendy; ChienChing Hung | Zendy; JannTay Wang | Zendy; Ming-Jui Tsai | Zendy; Po-Hsien Kuo | Zendy; TaiLing Chao | Zendy; SzuMin Hsieh | Zendy; WangHuei Sheng | Zendy; YeeChun Chen | Zendy; SuiYuan Chang | Zendy; ShanChwen Chang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19

Author(s) -

Wang-Da Liu,

ChienChing Hung,

JannTay Wang,

Ming-Jui Tsai,

Po-Hsien Kuo,

TaiLing Chao,

SzuMin Hsieh,

WangHuei Sheng,

YeeChun Chen,

SuiYuan Chang,

ShanChwen Chang

Publication year - 2021

Publication title -

journal of the formosan medical association

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.708

H-Index - 54

eISSN - 1876-0821

pISSN - 0929-6646

DOI - 10.1016/j.jfma.2021.04.010

Subject(s) - medicine , covid-19 , neutralizing antibody , antibody , virology , human immunodeficiency virus (hiv) , immune system , immune escape , immunology , infectious disease (medical specialty) , disease , outbreak

We presented the clinical course and immune responses of a well-controlled HIV-positive patient with COVID-19. The clinical presentation and antibody production to SARS-CoV-2 were similar to other COVID-19 patients without HIV infection. Neutralizing antibody reached a plateau from 26th to 47th day onset but decreased on 157th day after symptoms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research